We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-1.06%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$716M
AUM Growth
-$19.1M
Cap. Flow
+$8.71M
Cap. Flow %
1.22%
Top 10 Hldgs %
27.06%
Holding
107
New
3
Increased
17
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$11.4M
2
VCYT icon
Veracyte
VCYT
+$10M
3
LOW icon
Lowe's Companies
LOW
+$3.19M
4
CPN
Calpine Corporation
CPN
+$2.73M
5
LYB icon
LyondellBasell Industries
LYB
+$2.16M

Top Sells

Rank Stock Value
1
ROC
ROCKWOOD HLDGS INC
ROC
+$12.9M
2
SDRL
Seadrill Limited Common Stock
SDRL
+$9.17M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.54M
4
UFS
DOMTAR CORPORATION (New)
UFS
+$2.29M
5
SZYM
SOLAZYME INC COM STK (DE)
SZYM
+$1.82M

Sector Composition

Rank Sector Weight
1 Healthcare 29.21%
2 Technology 14.59%
3 Consumer Discretionary 13.52%
4 Industrials 8.55%
5 Energy 5.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPLN
51
Openlane
OPLN
$4.29B
$6.09M 0.85%
561,689
– –
TTPH
52
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$6M 0.84%
15,045
– –
NPSP
53
DELISTED
NPS PHARMACEUTICALS INC
NPSP
$5.82M 0.81%
223,900
– –
SRPT icon
54
Sarepta Therapeutics
SRPT
$1.64B
$5.47M 0.76%
259,100
– –
SCTY
55
DELISTED
SolarCity Corporation
SCTY
$5.3M 0.74%
89,000
– –
SGMO
56
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$5.2M 0.73%
482,500
– –
AZPN
57
DELISTED
ASPEN TECHNOLOGY INC
AZPN
$4.85M 0.68%
128,500
– –
LUMO
58
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$4.62M 0.65%
23,967
– –
CGNX icon
59
Cognex
CGNX
$10.4B
$4.03M 0.56%
200,000
– –
MGNX icon
60
MacroGenics
MGNX
$240M
$3.99M 0.56%
191,000
+26,200
+16% +$542K
AGTC
61
DELISTED
Applied Genetic Technologies Corporation
AGTC
$3.82M 0.53%
205,500
– –
CLDX icon
62
Celldex Therapeutics
CLDX
$3.02B
$3.74M 0.52%
19,247
– –
AKBA icon
63
Akebia Therapeutics
AKBA
$362M
$3.68M 0.51%
166,200
– –
RARE icon
64
Ultragenyx Pharmaceutical
RARE
$2.56B
$2.98M 0.42%
52,600
– –
CERN
65
DELISTED
Cerner Corp
CERN
$2.32M 0.32%
38,900
– –
ATRC icon
66
AtriCure
ATRC
$2.04B
$2.24M 0.31%
152,300
– –
SUPN icon
67
Supernus Pharmaceuticals
SUPN
$2.65B
$2.23M 0.31%
257,000
+16,400
+7% +$148K
NTUS
68
DELISTED
Natus Medical Inc
NTUS
$2.21M 0.31%
75,000
– –
BMRN icon
69
BioMarin Pharmaceuticals
BMRN
$11.7B
$2.18M 0.3%
30,200
– –
GWPH
70
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.02M 0.28%
25,000
– –
RGEN icon
71
Repligen
RGEN
$7.03B
$1.98M 0.28%
99,400
– –
HPTX
72
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$1.92M 0.27%
76,300
– –
CBST
73
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
$1.92M 0.27%
29,000
– –
XLRN
74
DELISTED
Acceleron Pharma
XLRN
$1.88M 0.26%
62,100
– –
SLXP
75
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$1.84M 0.26%
11,800
-10,000
-46% -$1.45M
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Eventide Asset Management held 107 positions worth $716M, down 2.6% from $735M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Eventide Asset Management's Q3 2014 filing shows 3 new, 17 increased, 4 reduced and 4 closed positions. Its largest new stake was Sage Therapeutics: 40,200 shares worth $1.27M. The largest sale was ROCKWOOD HLDGS INC, an estimated $12.9M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, up from 27% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Eventide Asset Management's largest Q3 2014 buy was Sage Therapeutics: 40,200 shares worth $1.27M.
  • Eventide Asset Management added most to bluebird bio in Q3 2014, an estimated $11.4M increase.
  • Eventide Asset Management's biggest Q3 2014 reduction was Agios Pharmaceuticals, cutting an estimated $2.54M.
  • Eventide Asset Management fully exited ROCKWOOD HLDGS INC in Q3 2014, selling an estimated $12.9M.
  • Eventide Asset Management's ten largest holdings make up 27% of its $716M portfolio in Q3 2014.
  • Eventide Asset Management opened 3 new positions and closed 4 in Q3 2014.
  • Eventide Asset Management's portfolio value fell 2.6% quarter-over-quarter to $716M.

Based on Eventide Asset Management's 13F filing for Q3 2014, filed 12 Nov 2014.